novo nordisk cagrisema

Novo Nordisk, FDA and Obesity

US FDA Says Shortage of Novo's Weight-Loss Drug Resolved

All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi

The New York Times · 16d

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Wall Street Journal · 11h

Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o

Reuters17d

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

BioSpace14d

After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

16don MSN

Novo doubles down on next-gen weight loss therapy despite early setback

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite disappointing early results. Read more here.

A Lawsuit Has Been Filed Against Novo Nordisk A/S For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of ...

pharmaphorum15d

Novo charts course ahead for CagriSema after lacklustre data

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Novo Nordisk: Dips Like These Come Once Every Few Years

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Novo Nordisk A/S to Contact the Firm Today!

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk A/S (NVO): A Bull Case Theory

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results